Mental Health DailyResearch. Evidence. Perspective.Published research on amyloid PET.
A 2026 review in the Japanese Journal of Radiology argued that amyloid PET has moved from an optional Alzheimer’s disease biomarker to a practical eligibility gate for anti-amyloid antibody …
Read articleA 2026 ADNI/A4 validation study found that Alzheimer’s plasma-biomarker machine-learning models still ranked amyloid PET status well across cohorts, but the practical rule-out number moved h…
Read articleLecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, co…
Read article
